 OUTLINE: Patients receive intranodal under ultrasound guidance or subcutaneous vaccinations of adjuvant electrofusion hybrids of autologous dendritic cells DC with autologous lymphoma cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, andor autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and 50. 